Advancements in Treating Fuchs’ Dystrophy
Exciting developments in the field of Fuchs’ dystrophy treatment have emerged, offering hope for patients. The University of Iowa Health Care has introduced a cutting-edge corneal transplant technique known as Descemet’s membrane endothelial keratoplasty (DMEK). This innovative procedure focuses on removing the dying endothelial cells, allowing healthier cells in the vicinity to replace them. By employing a simpler surgical approach, DMEK aims to enhance the effectiveness and success rate of the treatment.
The Origins of Fuchs’ Dystrophy
In 1910, Ernst Fuchs, an Austrian ophthalmologist, made significant contributions to the understanding of a condition characterized by corneal clouding. Fuchs documented the formation of epithelial blisters, the delayed onset of symptoms in later life, the gradual advancement of the disease, and other distinctive symptoms. Referred to as Fuchs’ dystrophy, this condition is also known as Fuchs’ corneal endothelial dystrophy (FCED) or Fuchs’ endothelial dystrophy (FED).